Vise Technologies Inc. Cuts Stake in GSK plc (NYSE:GSK)

Vise Technologies Inc. cut its position in GSK plc (NYSE:GSK) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,419 shares of the pharmaceutical company’s stock after selling 5,444 shares during the period. Vise Technologies Inc.’s holdings in GSK were worth $1,299,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Grimes & Company Inc. purchased a new stake in shares of GSK in the 4th quarter valued at approximately $4,731,000. Strategic Financial Concepts LLC purchased a new stake in shares of GSK in the 4th quarter valued at approximately $4,033,000. Kempner Capital Management Inc. increased its position in shares of GSK by 142.7% in the 4th quarter. Kempner Capital Management Inc. now owns 183,080 shares of the pharmaceutical company’s stock valued at $6,192,000 after purchasing an additional 107,648 shares during the last quarter. Stockman Wealth Management Inc. increased its position in shares of GSK by 3.7% in the 4th quarter. Stockman Wealth Management Inc. now owns 217,200 shares of the pharmaceutical company’s stock valued at $7,346,000 after purchasing an additional 7,683 shares during the last quarter. Finally, MADDEN SECURITIES Corp purchased a new stake in shares of GSK in the 4th quarter valued at approximately $2,957,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on GSK shares. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Hsbc Global Res raised shares of GSK to a “strong sell” rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 target price on the stock. Finally, Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.58.

GSK Trading Down 0.6%

NYSE GSK opened at $38.70 on Friday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm’s fifty day moving average price is $37.27 and its 200 day moving average price is $36.02. The company has a market capitalization of $79.84 billion, a price-to-earnings ratio of 24.34, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.45.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to analysts’ expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 EPS. On average, sell-side analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.36%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is currently 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.